On Tuesday, Akebia Therapeutics Inc (NASDAQ: AKBA) opened at On Tuesday, remained unchanged from the last session, before settling in for the closing price of $2.10. Price fluctuations for AKBA have ranged from $0.80 to $2.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -8.86% over the past five years. Company’s average yearly earnings per share was noted -9.12% at the time writing. With a float of $206.45 million, this company’s outstanding shares have now reached $211.54 million.
Let’s look at the performance matrix of the company that is accounted for 167 employees. In terms of profitability, gross margin is 63.13%, operating margin of -20.45%, and the pretax margin is -27.07%.
Akebia Therapeutics Inc (AKBA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Akebia Therapeutics Inc is 5.37%, while institutional ownership is 24.92%. The most recent insider transaction that took place on Feb 03 ’25, was worth 302,925. In this transaction CEO and President of this company sold 144,250 shares at a rate of $2.10, taking the stock ownership to the 2,604,330 shares. Before that another transaction happened on Feb 03 ’25, when Company’s SVP, Chief Medical Officer sold 50,506 for $2.10, making the entire transaction worth $106,063. This insider now owns 816,234 shares in total.
Akebia Therapeutics Inc (AKBA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -9.12% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Check out the current performance indicators for Akebia Therapeutics Inc (AKBA). In the past quarter, the stock posted a quick ratio of 1.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.16 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Akebia Therapeutics Inc (NASDAQ: AKBA) saw its 5-day average volume 1.35 million, a negative change from its year-to-date volume of 2.29 million. As of the previous 9 days, the stock’s Stochastic %D was 15.48%. Additionally, its Average True Range was 0.09.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 73.50%, which indicates a significant increase from 8.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.87% in the past 14 days, which was lower than the 57.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.02, while its 200-day Moving Average is $1.52. Nevertheless, the first resistance level for the watch stands at $2.12 in the near term. At $2.14, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.16. If the price goes on to break the first support level at $2.08, it is likely to go to the next support level at $2.06. The third support level lies at $2.04 if the price breaches the second support level.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are currently 218,181K shares outstanding in the company with a market cap of 458.18 million. Presently, the company’s annual sales total 194,620 K according to its annual income of -51,930 K. Last quarter, the company’s sales amounted to 37,430 K and its income totaled -20,040 K.
